ATROVENT HFA Drug Patent Profile

When do Atrovent Hfa patents expire, and what generic alternatives are available?

Atrovent Hfa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has ten patent family members in nine countries.

The generic ingredient in ATROVENT HFA is ipratropium bromide. There are eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Atrovent Hfa

A generic version of ATROVENT HFA was approved as ipratropium bromide by RITEDOSE CORP on January 26^th, 2001.

Summary for ATROVENT HFA

International Patents:	10
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	13
Clinical Trials:	47
Patent Applications:	4,700
Drug Prices:	Drug price information for ATROVENT HFA
DailyMed Link:	ATROVENT HFA at DailyMed

See drug prices for ATROVENT HFA

See drug sales revenues for ATROVENT HFA

Recent Clinical Trials for ATROVENT HFA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hat Yai Medical Education Center	Phase 3
Nationwide Children's Hospital	Phase 4
University of Nevada, Las Vegas	Phase 4

See all ATROVENT HFA clinical trials

Pharmacology for ATROVENT HFA

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

Paragraph IV (Patent) Challenges for ATROVENT HFA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ATROVENT HFA	Inhalation Aerosol	ipratropium bromide	0.21 mg/Inh	021527	1	2023-12-29

US Patents and Regulatory Information for ATROVENT HFA

ATROVENT HFA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	ATROVENT HFA	ipratropium bromide	AEROSOL, METERED;INHALATION	021527-001	Nov 27, 2004		RX	Yes	Yes	8,474,447		Y		Y

Expired US Patents for ATROVENT HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	ATROVENT HFA	ipratropium bromide	AEROSOL, METERED;INHALATION	021527-001	Nov 27, 2004	5,676,930
Boehringer Ingelheim	ATROVENT HFA	ipratropium bromide	AEROSOL, METERED;INHALATION	021527-001	Nov 27, 2004	6,983,743
Boehringer Ingelheim	ATROVENT HFA	ipratropium bromide	AEROSOL, METERED;INHALATION	021527-001	Nov 27, 2004	5,683,677
Boehringer Ingelheim	ATROVENT HFA	ipratropium bromide	AEROSOL, METERED;INHALATION	021527-001	Nov 27, 2004	6,739,333
Boehringer Ingelheim	ATROVENT HFA	ipratropium bromide	AEROSOL, METERED;INHALATION	021527-001	Nov 27, 2004	5,766,573
Boehringer Ingelheim	ATROVENT HFA	ipratropium bromide	AEROSOL, METERED;INHALATION	021527-001	Nov 27, 2004	5,695,743

International Patents for ATROVENT HFA

See the table below for patents covering ATROVENT HFA around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	403657
Hungary	E025069
Finland	952842
Eurasian Patent Organization	200101158
South Africa	9309195
European Patent Office	0673240	FORMULATIONS DE SOLUTIONS MEDICINALES AEROSOL STABILISEES (STABILIZED MEDICINAL AEROSOL SOLUTION FORMULATIONS)
Romania	117414	COMPOZITIE FARMACEUTICA DE AEROSOL IN SOLUTIE (PHARMACEUTICAL COMPOSITION OF GAS DISPERSOID IN SOLUTION)

ATROVENT HFA: Market Performance and Patent Landscape Analysis

Last updated: February 19, 2026

ATROVENT HFA, a metered-dose inhaler containing ipratropium bromide, is a bronchodilator used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). The drug's market performance is directly tied to its patent exclusivity, generic competition, and the evolving therapeutic landscape for COPD.

What is ATROVENT HFA's Current Market Position?

ATROVENT HFA holds a stable, albeit mature, position within the COPD market. Its long-standing presence and established efficacy have cemented its role as a rescue inhaler for managing acute bronchospasm. The primary market driver is the prevalence of COPD, a progressive lung disease characterized by airflow limitation.

Prevalence of COPD and Treatment Demand

The World Health Organization estimates that COPD affects approximately 251 million people globally [1]. This substantial patient population generates consistent demand for bronchodilator therapies. The aging global demographic further contributes to increasing COPD prevalence and, consequently, the demand for treatments like ATROVENT HFA.

Competitive Landscape

ATROVENT HFA competes with a range of bronchodilators, including short-acting beta-agonists (SABAs) and other short-acting muscarinic antagonists (SAMAs). Key competitors in the SAMA class include spiriva respimat (tiotropium bromide) for long-acting treatment and generic versions of ipratropium bromide. The development of long-acting bronchodilators (LABAs, LAMAs) and combination therapies has shifted the treatment paradigm towards maintenance therapy, but rescue inhalers remain critical.

Prescription Trends and Sales Data

Data from IQVIA and other market research firms indicate consistent prescription volumes for ipratropium bromide inhalers. While specific ATROVENT HFA sales figures are proprietary, the overall market for ipratropium bromide inhalers demonstrates a substantial revenue stream. The shift towards generics, however, exerts downward pressure on pricing and market share for branded products.

What is the Patent Exclusivity Status of ATROVENT HFA?

The patent exclusivity for ATROVENT HFA has largely expired, leading to increased generic competition. The original patents covering the ipratropium bromide molecule and its use in inhalation have long since lapsed.

Original Patent Expirations

The core patents for ipratropium bromide, a substance discovered in the late 1960s, expired decades ago. This paved the way for generic manufacturers to develop and market their own versions of ipratropium bromide inhalers.

Formulation and Delivery System Patents

While the active pharmaceutical ingredient (API) is off-patent, manufacturers may have held patents related to specific formulations or delivery devices. For ATROVENT HFA, patents covering the hydrofluoroalkane (HFA) propellant system would have been critical for maintaining market exclusivity for a period. These patents likely expired at various points over the years.

Generic Market Entry and Impact

The entry of generic ipratropium bromide inhalers has significantly impacted the market for branded ATROVENT HFA. Generic products, typically offered at lower price points, capture a substantial portion of the market share. This necessitates a focus on cost-effectiveness and patient access for generic manufacturers.

Year	Key Patent Event/Observation
Pre-2000	Expiration of core ipratropium bromide molecule patents.
Early 2000s	Introduction of HFA-based inhaler technology, potentially with associated patent protection.
Mid-2010s onwards	Widespread generic entry for ipratropium bromide inhalers, including HFA formulations.

Note: Specific patent numbers and expiry dates are not publicly disclosed for all historical patents but the general trend of expiry is well-established.

What are the Financial Projections and Market Trajectory?

The financial trajectory of ATROVENT HFA is characterized by declining revenue from the branded product due to generic erosion, while the overall ipratropium bromide market remains significant due to sustained COPD prevalence.

Revenue Decline for Branded ATROVENT HFA

As generic ipratropium bromide inhalers become more prevalent, the sales revenue for the branded ATROVENT HFA product has experienced a downward trend. This is a common phenomenon for branded pharmaceuticals following patent expiration and the subsequent entry of lower-cost alternatives.

Market Size for Ipratropium Bromide Inhalers

The total market size for ipratropium bromide inhalers, encompassing both branded and generic versions, remains robust. This is driven by:

• High COPD Incidence: A large and growing patient population requiring bronchodilator therapy.
• Cost-Effectiveness of Generics: Generic ipratropium bromide offers an affordable treatment option, making it accessible to a wider patient base.
• Established Treatment Guidelines: Ipratropium bromide is a recommended therapy in COPD treatment guidelines for symptom relief and rescue use.

Future Market Outlook

The market for ipratropium bromide inhalers is expected to remain stable, with growth driven primarily by population increases and COPD prevalence. The branded ATROVENT HFA will likely see continued market share erosion as generics dominate. Manufacturers of generic ipratropium bromide can expect sustained demand. The development of novel COPD therapies could eventually influence the demand for older bronchodilators, but ipratropium bromide's role as a rescue inhaler is likely to persist for the foreseeable future.

What are the Regulatory Considerations for ATROVENT HFA and its Generics?

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a crucial role in approving and monitoring both branded and generic versions of ATROVENT HFA.

FDA Approval Pathway for Generics

Generic versions of ATROVENT HFA must demonstrate bioequivalence to the reference listed drug (RLD), which is the branded ATROVENT HFA. This involves conducting clinical studies to show that the generic product delivers the same amount of active ingredient into the bloodstream in the same amount of time as the RLD. The FDA's Abbreviated New Drug Application (ANDA) process allows for this without requiring extensive clinical trials for efficacy and safety, provided bioequivalence is established.

Manufacturing Standards and Quality Control

Both branded and generic manufacturers must adhere to stringent Current Good Manufacturing Practices (cGMP) regulations. This ensures the quality, safety, and efficacy of the finished drug product. Regulatory inspections and quality control testing are ongoing processes.

Labeling and Indication Requirements

Generic drug labeling must be the same as the RLD's labeling, except for minor changes that are not material to safety or effectiveness. The approved indications for use also remain the same.

Post-Market Surveillance

Regulatory agencies monitor the safety of all approved drugs, including ATROVENT HFA and its generics, through post-market surveillance systems. This includes tracking adverse event reports to identify any potential safety issues that may arise after a drug is on the market.

Key Takeaways

• ATROVENT HFA is a mature COPD medication facing significant generic competition due to the expiration of its core patents.
• The demand for ipratropium bromide inhalers remains strong, driven by the high global prevalence of COPD.
• Branded ATROVENT HFA revenue is declining, while the generic market for ipratropium bromide is stable and significant.
• Generic approval requires demonstrating bioequivalence to the reference product, with ongoing adherence to manufacturing and quality standards.

Frequently Asked Questions

1. Will ATROVENT HFA be discontinued? Branded ATROVENT HFA is unlikely to be discontinued in the short term but will continue to see market share decline as generics dominate. Production may cease if the economic viability for the manufacturer diminishes significantly.

2. What are the main differences between ATROVENT HFA and generic ipratropium bromide inhalers? The primary difference is price. Generic versions are therapeutically equivalent and have the same active ingredient and dosage form, but are sold at lower costs. Inactive ingredients or device design may vary slightly between products.

3. Are there any newer inhaler technologies that are replacing ipratropium bromide? While newer long-acting bronchodilators and combination therapies are standard for COPD maintenance, ipratropium bromide remains a frontline rescue inhaler for acute bronchospasm due to its rapid onset of action and established safety profile.

4. What is the typical cost difference between ATROVENT HFA and its generic equivalents? Generic ipratropium bromide inhalers can be 50-90% less expensive than branded ATROVENT HFA, depending on the pharmacy, insurance coverage, and specific product.

5. What is the expected lifespan of ipratropium bromide as a COPD treatment? Given its efficacy as a rescue inhaler and its affordability in generic form, ipratropium bromide is expected to remain a relevant treatment option for COPD symptom management for the foreseeable future.

Citations

[1] World Health Organization. (2023). Chronic obstructive pulmonary disease (COPD). https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)